The cost of mapping a person’s full genetic profile has been dropping quickly. Now, doctors are struggling with a new question: how to use the information to improve people’s health.
If you like this story, please see our blog titled “Genetic Sequencing – 3 Ways it Will Enable a New Future for Medicine”
Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.
If you like this story, please see our blog titled “Quality vs. Cost in Biopharmaceutical Manufacturing Ways to Achieve Both”
A lot of people think tuberculosis is a thing of the past, but it remains one of the most deadly diseases in the world. Now the Seattle-based Infectious Disease Research Institute is getting ready to take it on with a new vaccine being prepped for clinical trials.
If you like this story, please see our blog titled “Improving Media to Increase Virus Yield in Vaccine Production”
A new treatment that involves spinning bone marrow stem cells to enhance their healing potential may help people with advanced heart failure feel and function better, a small study suggests.
If you like this story, please see our stem cell blog titled “Fetal Stem Cells Could be Most Effecitve in Heart Treatment”
It may be possible to use “stem cell shielding” to protect the body from the damaging effects of chemotherapy, early results from a US trial suggest.
If you like this story, please see our blog titled “Culture and Expansion of Stem Cells in Stirred Suspension Bioreactors Could Provide Key in Large Scale Manufacturing”
Patient safety must be “a non-negotiable priority” for the US Food and Drug Administration (FDA) and drugmakers as they seek to bring biosimilar medicines to market, and that focus “does not end with drug approval,” regulators have been told.
If you like this story, please see our stem cell blog titled “Comments on Biosimilar Guidance Indicate Discontent on Both Sides of the Issues”
While the biosimilars manufacturing industry “is at a nascent stage”, the impending patent expiries on big-selling biologics will result in the introduction of several new versions and provide impetus to market development. That is the view of researchers at Frost & Sullivan who have issued a new analysis of the European biosimilars market. The report claims the latter enjoyed revenues of $172.0 million in 2010 and estimates this to reach approximately $3.99 billion in 2017, representing a compound annual growth rate (CAGR) of 56.7%.
If you like this story, please see our blog titled “FDA Issues Biosimilar Approval Guidelines”